Ocular Surface Reports

The “2025 Dry Eye Pharmaceuticals Market Report” provides a comprehensive analysis of the global market for dry eye therapeutics, examining the disease’s prevalence, diagnosis, and treatment landscape. The report provides in-depth coverage of artificial tears, anti-inflammatory drops, miticides, tear evaporation inhibitors, mucin secretagogues, and other prescription and over-the-counter products—with detailed forecasts of unit demand, sales revenue, and market performance by region through 2030. 

The report offers a data-driven assessment of the current dry eye marketplace and its growth potential, highlighting new product development, emerging drug-delivery methods, and the expanding pharmaceutical pipeline. Global and regional forecasts are presented for seven major regions, with coverage of competitive dynamics, regulatory differences, and therapeutic trends. Profiles are provided for 23 leading companies and their strategic positioning within the dry eye market. 

The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking. 

It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations. 

This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment. 

Market Scope surveyed ophthalmologists and optometrists in the US and Western Europe (WE) during July and August 2025 to measure patients they were seeing and screening for ocular surface disease; adoption of treatments; and insight into the latest market trends. 

Ophthalmologists and optometrists from most specialties (cataract, refractive, retina, dry eye glaucoma, and comprehensive) who self-registered on market-scope.com were invited to participate in the annual sponsored survey. 

An email invitation was sent on July 25, 2025, and a last call went out on Aug. 8, 2025. We received 198 total complete, unique responses—158 from the US and 40 from WE. All results were calculated based on respondent count; because not all questions were applicable to all providers, the respondent count (n) may vary throughout the survey. 

Survey reports are strictly a summary analysis of the reported data, and no additional extrapolation to the overall market was performed. All survey data are de-identified and maintained on a secure server.